



## Seaport Therapeutics Presents Data Further Validating Glyph™ Platform's Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

December 8, 2025

*Preclinical data presented at the American Epilepsy Society (AES) Annual Meeting provide additional evidence supporting Glyph's ability to be applied across a wide range of molecules*

*Application of Glyph shown to enhance the oral bioavailability of cannabidiol (CBD) and significantly reduce seizure activity at a CBD dose three times lower than non-Glyph oral CBD*

**Boston, MA – December 8, 2025** – [Seaport Therapeutics](#), a clinical-stage therapeutics company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the presentation of preclinical data further demonstrating that its proprietary Glyph™ platform was successfully applied to another class of clinically validated molecules previously held back by poor drug-like properties. The findings, presented at the 2025 American Epilepsy Society (AES) Annual Meeting, show that the application of Glyph to create an oral prodrug of cannabidiol (CBD), a clinically validated anti-epileptic drug constrained by low oral bioavailability, hepatotoxicity and gastrointestinal side effects, enhanced pharmacokinetic properties and significantly improved anti-seizure activity at lower CBD doses, underscoring Glyph's broad potential to create better medicines across multiple indications.

GlyphCBD™ (SPT-310 or Glyph Cannabidiol), a Glyphed oral prodrug of cannabidiol (CBD), was evaluated in the maximal electroshock model (MES), a validated and translatable preclinical model that is widely accepted for the assessment of anti-seizure drugs. In a head-to-head comparison, GlyphCBD demonstrated strong seizure protection and was shown to prevent seizures at a median effective CBD dose three times lower than a non-Glyph oral CBD formulation. These results suggest that GlyphCBD can deliver therapeutic efficacy in reduced formulation volumes, lowering the risk of hepatotoxicity and gastrointestinal side effects, and expanding the therapeutic potential of CBD to broader patient populations and additional indications.

Glyph is Seaport's lymphatic-targeting prodrug platform that has been clinically validated. It uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism, otherwise leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity.

"These findings provide additional evidence supporting the broad applicability of the Glyph platform to improve oral drug delivery across a wide range of therapeutic molecules," said Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics. "By avoiding first-pass metabolism, we can unlock the full therapeutic potential of clinically validated mechanisms that were previously constrained by limitations that Glyph is uniquely designed to solve. Leveraging the power of this platform, we can explore additional applications in CNS and non-CNS diseases to address significant unmet needs, including expanding the treatment options for seizures resulting from certain rare conditions."

CBD is currently approved to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in the United States and European Union, but standard formulations exhibit low oral bioavailability and require patients to swallow large volumes of sesame oil-based solutions, which can lead to hepatotoxicity and gastrointestinal adverse events. Based on the data, GlyphCBD has the potential to improve the overall safety profile of CBD while retaining therapeutic efficacy and expanding clinical use to broad patient populations.

Beyond the CNS, potential applications for Glyph include oncology, immunology and inflammation, and metabolic disease.

### About the Glyph™ Platform

Glyph is Seaport's proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism otherwise leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. For each program, Seaport leverages its Glyph platform to create unique sets of prodrugs with differentiated profiles, including lymphatic transport and conversion characteristics, as potential candidates to advance into preclinical and clinical proof-of-concept studies. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company's pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in [Nature Metabolism](#), [Frontiers in Pharmacology](#), [Journal of Controlled Release](#) and [Molecular Pharmaceutics](#) supporting the Glyph platform's capabilities. See Glyph in action [here](#).

## **About Seaport Therapeutics**

Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit [www.seaportx.com](http://www.seaportx.com).